Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
An old cancer drug's degrading new look: Typically, cancer drugs that help only a small number of patients in clinical trials are not pursued. This might change in a future world of precision medicine, where biomarkers will match specific drugs to the patients most likely to respond. Han et al. identified the mechanism of action of a cancer drug called indisulam, a sulfonamide tested previously in patients with solid tumors. Indisulam and related sulfonamides killed cells by disrupting precursor mRNA splicing. The drugs targeted a specific RNA splicing factor for degradation by “gluing” it to the CUL4-DCAF15 ubiquitin ligase. Experiments with cancer cell lines suggest that future clinical trials of these drugs should focus on leukemias and lymphomas with high DCAF15 expression levels. Science , this issue p. eaal3755
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, aryl sulphonamides degrade the essential RNA-binding protein RBM39 by engaging DCAF15, the substrate receptor of the CRL4DCAF15 E3 ubiquitin ligase13–15.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [13]
In the citing paper
“it took two decades to determine that indisulam, and the related sulfonamides e7820 and chloroquinoxaline sulfonamide (cQS), were in fact glue degraders that targeted the splicing factor RBM39 (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“indisulam facilitated an interaction between RBM39 and DcAF15, a substrate receptor component of the cRl4 DcAF15 ligase complex (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“However, sulfonamides such as indisulam and similar SPlAMs were serendipitously discovered to degrade RBM39 by stabilizing its native interaction with cRl4 DcAF15 (Han et al. 2017; uehara et al. 2017) (Figure 4A).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“The same MG mechanism has subsequently been revealed for antitumor aryl-sulfonamides, which reprograms another CRL4 substrate receptor, DCAF15, to bind and degrade certain RNA-binding proteins21–26.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [21]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Shevchenko, A., Wilm, M., Vorm, O., & Mann, M. (1996) · Analytical Chemistry · doi:10.1021/ac950914h · Cited by 8,995
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484
NGS QC Toolkit: A Toolkit for Quality Control of Next Generation Sequencing Data
Patel, R. K., & Jain, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030619 · Cited by 2,917
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Auxin regulates SCFTIR1-dependent degradation of AUX/IAA proteins
Gray, W. M., Kepinski, S., Rouse, D., Leyser, O., & Estelle, M. (2001) · Nature · doi:10.1038/35104500 · Cited by 1,413
Building ubiquitin chains: E2 enzymes at work
Ye, Y., & Rape, M. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2780 · Cited by 989
Correlating chemical sensitivity and basal gene expression reveals mechanism of action
Rees, M. G., Seashore-Ludlow, B., Cheah, J. H., Adams, D. J., Price, E. V., Gill, S., Javaid, S., Coletti, M. E., Jones, V. L., Bodycombe, N. E., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1986 · Cited by 898
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
Basu, A., Bodycombe, N. E., Cheah, J. H., Price, E. V., Liu, K., Schaefer, G. I., Ebright, R. Y., Stewart, M. L., Ito, D., Wang, S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.003 · Cited by 833
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701
RNA splicing factors as oncoproteins and tumour suppressors
Dvinge, H., Kim, E., Abdel-Wahab, O., & Bradley, R. K. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.51 · Cited by 687
Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery
Angers, S., Li, T., Yi, X., MacCoss, M. J., Moon, R. T., & Zheng, N. (2006) · Nature · doi:10.1038/nature05175 · Cited by 674
Rapid protein depletion in human cells by auxin-inducible degron tagging with short homology donors
Natsume, T., Kiyomitsu, T., Saga, Y., & Kanemaki, M. T. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.001 · Cited by 673
Splicing factor SF3b as a target of the antitumor natural product pladienolide
Kotake, Y., Sagane, K., Owa, T., Mimori-Kiyosue, Y., Shimizu, H., Uesugi, M., Ishihama, Y., Iwata, M., & Mizui, Y. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.16 · Cited by 657
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA
Kaida, D., Motoyoshi, H., Tashiro, E., Nojima, T., Hagiwara, M., Ishigami, K., Watanabe, H., Kitahara, T., Yoshida, T., Nakajima, H., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.18 · Cited by 650
Proteomics: the move to mixtures
Peng, J., & Gygi, S. P. (2001) · Journal of Mass Spectrometry · doi:10.1002/jms.229 · Cited by 648
Jin, J., Arias, E. E., Chen, J., Harper, J. W., & Walter, J. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.010 · Cited by 632
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620
Therapeutic targeting of splicing in cancer
Lee, S. C.-W., & Abdel-Wahab, O. (2016) · Nature Medicine · doi:10.1038/nm.4165 · Cited by 561
Global Identification of Modular Cullin-RING Ligase Substrates
Emanuele, M. J., Elia, A. E. H., Xu, Q., Thoma, C. R., Izhar, L., Leng, Y., Guo, A., Chen, Y.-N., Rush, J., Hsu, P. W.-C., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.019 · Cited by 404
Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle
Owa, T., Yoshino, H., Okauchi, T., Yoshimatsu, K., Ozawa, Y., Sugi, N. H., Nagasu, T., Koyanagi, N., & Kitoh, K. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9902638 · Cited by 322
Abbate, F., Casini, A., Owa, T., Scozzafava, A., & Supuran, C. T. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.062 · Cited by 262
An intact NEDD8 pathway is required for Cullin‐dependent ubiquitylation in mammalian cells
Ohh, M., Kim, W. Y., Moslehi, J. J., Chen, Y., Chau, V., Read, M. A., & Kaelin, W. G. (2002) · EMBO reports · doi:10.1093/embo-reports/kvf028 · Cited by 177
Using transcriptome sequencing to identify mechanisms of drug action and resistance
Wacker, S. A., Houghtaling, B. R., Elemento, O., & Kapoor, T. M. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.779 · Cited by 160
E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo
Ozawa, Y., Sugi, N. H., Nagasu, T., Owa, T., Watanabe, T., Koyanagi, N., Yoshino, H., Kitoh, K., & Yoshimatsu, K. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00275-1 · Cited by 132
Imai, H., Chan, E. K. L., Kiyosawa, K., Fu, X., & Tan, E. M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116848 · Cited by 122
The antitumor toxin CD437 is a direct inhibitor of DNA polymerase α
Han, T., Goralski, M., Capota, E., Padrick, S. B., Kim, J., Xie, Y., & Nijhawan, D. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2082 · Cited by 114
Self-citationFukuoka, K., Usuda, J., Iwamoto, Y., Fukumoto, H., Nakamura, T., Yoneda, T., Narita, N., Saijo, N., & Nishio, K. (2001) · Investigational New Drugs · doi:10.1023/a:1010608317361 · Cited by 112
Identification of Substrates for F‐Box Proteins
Jin, J., Cambronne, X. A., Shirogane, T., & Harper, J. W. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)99020-4 · Cited by 91
A Gatekeeper Residue for NEDD8-Activating Enzyme Inhibition by MLN4924
Toth, J. I., Yang, L., Dahl, R. S., & Petroski, M. D. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.02.006 · Cited by 84
Talbot, D. C., von Pawel, J., Cattell, E., Yule, S. M., Johnston, C., Zandvliet, A. S., Huitema, A. D. R., Norbury, C. J., Ellis, P., Bosquée, L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0249 · Cited by 83
Domanski, M., Molloy, K. R., Jiang, H. L., Chait, B. T., Rout, M. P., Jensen, T. H., & LaCava, J. (2012) · BioTechniques · doi:10.2144/000113864 · Cited by 66
Haddad, R. I., Weinstein, L. J., Wieczorek, T. J., Bhattacharya, N., Raftopoulos, H., Oster, M. W., Zhang, X., Latham, V. M., Costello, R., Faucher, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0229 · Cited by 66
LaCava, J., Molloy, K. R., Taylor, M. S., Domanski, M., Chait, B. T., & Rout, M. P. (2015) · BioTechniques · doi:10.2144/000114262 · Cited by 64
Raymond, É., Huinink, W. W. T. B., Taïeb, J., Beijnen, J. H., Faivre, S. J., Wanders, J., Ravic, M., Fumoleau, P., Armand, J., & Schellens, J. H. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.030 · Cited by 62
Phase II study of E7070 in patients with metastatic melanoma
Smyth, J. F., Aamdal, S., Awada, A. H., Dittrich, C., Caponigro, F., Schöffski, P., Gore, M. E., Lesimple, T., Djurasinovic, N., Barón, B., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdi016 · Cited by 59
Punt, C. J. A., Fumoleau, P., van de Walle, B., Faber, M. N., Ravic, M., & Campone, M. (2001) · Annals of Oncology · doi:10.1023/a:1012287111922 · Cited by 57
Dittrich, C., Dumez, H., Calvert, H., Hanauske, A.-R., Faber, M. N., Wanders, J., Yule, M., Ravic, M., & Fumoleau, P. (2003) · PubMed · doi:10.25405/ncl.34651815 · Cited by 50
Terret, C., Zanetta, S., Roche, H. H., Schellens, J. H. M., Faber, M. N., Wanders, J., Ravic, M., & Droz, J. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00128-x · Cited by 47
Kirkwood, J. M., Gonzalez, R. C., Reintgen, D. S., Clingan, P. R., McWilliams, R. R., de Alwis, D. P., Zimmermann, A. H., Brown, M. P., Ilaria, R. L., & Millward, M. J. (2011) · Cancer · doi:10.1002/cncr.26068 · Cited by 31
Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days
Yamada, Y., Yamamoto, N., Shimoyama, T., Horiike, A., Fujisaka, Y., Takayama, K., Sakamoto, T., Nishioka, Y., Yasuda, S., & Tamura, T. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00109.x · Cited by 30
Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide.
Rigas, J. R., Tong, W. P., Kris, M. G., Orazem, J. P., Young, C. W., & Warrell, R. P. (1992) · PubMed · Cited by 30
Novel acyl sulfonamide LY573636-sodium: Effect on hematopoietic malignant cells
Gueller (1994) · Oncology Reports · doi:10.3892/or_00000135 · Cited by 20
Simon, G. R., Ilaria, R. L., Sovak, M. A., Williams, C. C., Haura, E. B., Cleverly, A. L., Sykes, A. K., Wagner, M. M., de Alwis, D. P., Slapak, C. A., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1593-0 · Cited by 19
Bekaii‐Saab, T., Mortazavi, A., Hicks, L. G., Zalupski, M. M., Pelley, R. J., Chan, K. K., & Kraut, E. H. (2006) · Investigational New Drugs · doi:10.1007/s10637-005-4827-3 · Cited by 15
Miller, V. A., Rigas, J. R., Tong, W. P., Reid, J. R., Pisters, K. M. W., Grant, S. C., Heelan, R. T., & Kris, M. G. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050679 · Cited by 15
Cited by
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Goodall, G. J., & Wickramasinghe, V. O. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00306-0 · Cited by 1,066
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
Roles and mechanisms of alternative splicing in cancer — implications for care
Bonnal, S. C., López-Oreja, I., & Valcárcel, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0350-x · Cited by 731
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K.-S., Kaniskan, H. Ü., Xiong, Y., & Jin, J. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00365-x · Cited by 632
Metadata
- Authors
- Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Goralski, Maria
- Gaskill, Nicholas
- Nijhawan, Deepak
- ORCID
- Venue
- Science
- Published
- 2017-04-28
- Volume
- 356
- Issue
- 6336
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2596064219
- Cited by
- 762
- References
- 55
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 122 · 2023: 99 · 2022: 86 · 2021: 99 · 2020: 86 · 2019: 56 · 2018: 40 · 2017: 15
- FWCI
- 22.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Welch Foundation (I-1879)
- Damon Runyon Cancer Research Foundation (CI-68-13)
- Cancer Prevention and Research Institute of Texas (RP150596)
- Life Sciences Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- indisulam, sulfonamides, RBM39, DCAF15, pre-mRNA splicing, splicing inhibition, proteasomal degradation, polyubiquitination, anticancer agents, drug resistance, biomarkers
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Nuclear Proteins, RNA Splicing, Sulfonamides, RNA-Binding Proteins, Mice, Knockout, Drug Resistance, Neoplasm, Amino Acid Substitution, Xenograft Model Antitumor Assays, Ubiquitin-Protein Ligase Complexes, Cell Line, Tumor, Proteasome Endopeptidase Complex, Mice, Biomarkers, Pharmacological, Ubiquitination, Molecular Targeted Therapy, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.